273 related articles for article (PubMed ID: 27849387)
1. SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
Arslan MS; Sahin M; Karakose M; Tutal E; Topaloglu O; Ucan B; Demirci T; Caliskan M; Ozdemir S; Ozbek M; Cakal E
Endocr Pract; 2017 Mar; 23(3):266-370. PubMed ID: 27849387
[TBL] [Abstract][Full Text] [Related]
2. Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma.
Ozer FF; Dagdelen S; Erbas T
Horm Metab Res; 2018 Jul; 50(7):562-567. PubMed ID: 29895074
[TBL] [Abstract][Full Text] [Related]
3. OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.
Karalazou P; Ntelios D; Chatzopoulou F; Fragou A; Taousani M; Mouzaki K; Galli-Tsinopoulou A; Kouidou S; Tzimagiorgis G
Ital J Pediatr; 2019 Dec; 45(1):161. PubMed ID: 31823791
[TBL] [Abstract][Full Text] [Related]
4. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
5. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
6. The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.
Fahrleitner-Pammer A; Dobnig H; Dimai HP; Holzer H; Benesch T; Borchhardt K; Cejka D; Haas M
Clin Nephrol; 2009 Jun; 71(6):652-9. PubMed ID: 19473634
[TBL] [Abstract][Full Text] [Related]
7. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease.
Siomou E; Challa A; Printza N; Giapros V; Petropoulou F; Mitsioni A; Papachristou F; Stefanidis CJ
Pediatr Nephrol; 2011 Jul; 26(7):1105-14. PubMed ID: 21479768
[TBL] [Abstract][Full Text] [Related]
9. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
10. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
11. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
[TBL] [Abstract][Full Text] [Related]
12. Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women.
Mainini G; Incoronato M; Urso L; Scaffa C
Clin Exp Obstet Gynecol; 2011; 38(4):355-9. PubMed ID: 22268274
[TBL] [Abstract][Full Text] [Related]
13. Low bone mineral density is associated to poor glycemic control and increased OPG expression in children and adolescents with type 1 diabetes.
Loureiro MB; Ururahy MA; Freire-Neto FP; Oliveira GH; Duarte VM; Luchessi AD; Brandão-Neto J; Hirata RD; Hirata MH; Maciel-Neto JJ; Arrais RF; Almeida MG; Rezende AA
Diabetes Res Clin Pract; 2014 Mar; 103(3):452-7. PubMed ID: 24529565
[TBL] [Abstract][Full Text] [Related]
14. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.
Angelopoulos NG; Goula A; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Malaktari S; Athanasiou V; Tolis G
J Bone Miner Metab; 2007; 25(1):60-7. PubMed ID: 17187195
[TBL] [Abstract][Full Text] [Related]
15. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
16. Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study.
Amer OE; Wani K; Ansari MGA; Alnaami AM; Aljohani N; Abdi S; Hussain SD; Al-Daghri NM; Alokail MS
Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 35893092
[TBL] [Abstract][Full Text] [Related]
17. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
Spelling P; Bonfá E; Caparbo VF; Pereira RM
Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
